Stop Juggling 6 Calculators: The HCC Master Calculator Does It All
Enter patient data once. Get Child-Pugh, ALBI, MELD-Na, BCLC (2022), HKLC, and Milan Criteria results instantly. One tool, complete HCC assessment.
The Problem: Too Many Calculators, Too Little Time
Sound Familiar?
You're assessing an HCC patient. You open one tab for Child-Pugh. Another for MELD. A third for BCLC staging. Then ALBI. Then Milan Criteria for transplant eligibility...
Before you know it, you're entering the same bilirubin and albumin values into 5 different calculators, switching between tabs, and hoping you didn't make a transcription error along the way.
The reality of HCC management:
- Multiple scoring systems are clinically necessary
- Each system serves a different purpose
- Re-entering the same lab values wastes precious time
- Manual data entry across tools introduces error risk
The Solution: One Calculator to Rule Them All
Introducing the HCC Master Calculator
Enter your patient's data once. Get six validated scoring systems calculated simultaneously.
- Child-Pugh Score
- ALBI Grade
- MELD-Na Score
- BCLC Staging (2022 Update)
- HKLC Staging
- Milan Criteria
What's Inside: 6 Integrated Scoring Systems
Child-Pugh Score
The gold standard for assessing cirrhosis severity. Classifies patients into Class A, B, or C with corresponding survival estimates.
ALBI Grade
An objective, lab-only assessment of liver function. No subjective clinical variables means more reproducible results.
MELD-Na Score
The OPTN standard for liver transplant prioritization. Predicts 3-month mortality in end-stage liver disease.
BCLC Staging (2022 Update)
The Western standard for HCC staging with direct treatment recommendations. Updated to include systemic therapy guidance.
HKLC Staging
The Hong Kong system that often recommends more aggressive treatment for intermediate stages. Essential for complete staging perspective.
Milan Criteria
The worldwide standard for liver transplant eligibility in HCC. Instantly know if your patient qualifies.
Key Benefits
Faster Assessment
Enter data once instead of five times across different tools
Transcription Errors
Single data entry eliminates copy-paste mistakes
Updated Guidelines
BCLC reflects the latest treatment recommendations
Who Should Use This Calculator?
Clinical Teams
- ✓Hepatologists managing cirrhotic patients
- ✓Oncologists treating hepatocellular carcinoma
- ✓Transplant surgeons evaluating candidates
- ✓Interventional radiologists planning TACE
Use Cases
- ✓Multidisciplinary tumor board presentations
- ✓Pre-operative risk assessment
- ✓Transplant workup and listing decisions
- ✓Clinical trial eligibility screening
How It Works
Enter Laboratory Values
Input bilirubin, albumin, INR, creatinine, and sodium from your patient's labs.
Add Clinical Findings
Select ascites status, encephalopathy grade, and ECOG performance status.
Enter Tumor Details
Specify tumor count, maximum size, vascular invasion, and metastasis status.
Get Complete Results
View all six scoring systems with interpretations, treatment recommendations, and prognosis estimates.
Frequently Asked Questions
What if I'm missing some laboratory values?
The calculator handles missing data intelligently:
- Child-Pugh: Requires all 5 inputs. No assumptions are made for missing values to ensure accuracy.
- BCLC & HKLC: Depend on Child-Pugh. If Child-Pugh can't be calculated, these will show as N/A.
- MELD-Na: If sodium is missing, you'll get the Base MELD score with a note that sodium correction wasn't applied.
- ALBI: Only needs albumin and bilirubin, so it's often available even with limited labs.
Is the BCLC staging up-to-date with the latest guidelines?
Yes! The calculator implements the 2022 BCLC update (Reig M, et al. J Hepatol 2022), which includes:
- Recognition of systemic therapy for select intermediate-stage patients
- Atezolizumab + Bevacizumab as standard for advanced stages
- Updated treatment algorithm reflecting current clinical practice
When should I use BCLC vs HKLC staging?
Both systems have value, which is why we include both:
- BCLC: The Western standard, endorsed by EASL and AASLD. Conservative approach to surgical candidacy.
- HKLC: Developed in Hong Kong, often recommends more aggressive treatment (especially resection) for intermediate stages.
For a complete picture, review both. A patient classified as "BCLC Stage B (TACE)" might be "HKLC Stage IIa (Resection candidate)" - this discordance is clinically meaningful.
How does the calculator determine transplant eligibility?
We provide two key metrics for transplant assessment:
- Milan Criteria: Binary assessment (Within/Outside) based on tumor burden. Patients within criteria have 75-85% 4-year post-transplant survival.
- MELD-Na: Determines priority on the transplant waiting list. Higher scores = higher urgency.
Together, these tell you if a patient qualifies (Milan) and how urgently they need listing (MELD-Na).
Can I use this for clinical decision-making?
The HCC Master Calculator is designed as a clinical support tool. All calculations use validated, published formulas with proper references. However:
- Always verify critical calculations independently
- Clinical judgment should guide final treatment decisions
- Consider patient-specific factors not captured in scoring systems
- Discuss complex cases in multidisciplinary tumor boards
What units does the calculator use?
The calculator uses SI units (International System), which is standard in most countries:
- Bilirubin: µmol/L
- Albumin: g/L
- Creatinine: µmol/L
- Sodium: mmol/L
If your lab reports in mg/dL, you'll need to convert before entering values.
Ready to Simplify Your HCC Assessments?
Stop switching between calculators. Get complete staging in seconds.
Try the HCC Master Calculator Now
Free to use. No registration required.
References
1. Pugh RN, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649.
2. Johnson PJ, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-558.
3. Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470.
4. Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693.
5. Yau T, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691-1700.
6. Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693-699.